2 citations
,
December 2024 in “International Journal of Rheumatic Diseases” Ocrelizumab may cause total body hair loss in some patients.
1 citations
,
January 2017 in “Expert opinion on orphan drugs” Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.
156 citations
,
August 2014 in “Cochrane library” Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.
39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
278 citations
,
March 2013 in “Gut” Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
1 citations
,
October 2023 in “European Journal of Dermatology” Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.
May 2026 in “SHILAP Revista de lepidopterología” Dupilumab effectively treated severe alopecia areata in a child.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
Baricitinib is more effective than methotrexate for severe alopecia areata.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
19 citations
,
January 2019 in “JAAD case reports” A medication for skin rash also unexpectedly treated hair loss in a patient.
13 citations
,
July 2019 in “Dermatologic therapy” Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.
9 citations
,
July 2018 in “European Journal of Dermatology” Brodalumab effectively treated a man's severe hand and foot psoriasis.
May 2015 in “Journal of The American Academy of Dermatology” Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
4 citations
,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.